Cyclooxygenase-2 inhibitors dilemma in cardiovascular medicine: Are all family members bad players?
International Journal of Cardiology, cilt.116, sa.2, ss.259-260, 2007 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 116 Sayı: 2
- Basım Tarihi: 2007
- Doi Numarası: 10.1016/j.ijcard.2006.02.021
- Dergi Adı: International Journal of Cardiology
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.259-260
- Anahtar Kelimeler: cyclooxygenase-2 inhibitors, coronary artery disease, cardiovascular medicine
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Cyclooxygenase-2 (COX-2) inhibitors dilemna in cardiovascular medicine has not been resolved yet. The cardiovascular safety of selective COX-2 inhibitors other than rofecoxib is uncertain. Given the ongoing controversy surrounding the use of COX-2 inhibitors, futher clinical studies with different types of drugs are required to establish safety and therapeutic benefit in patients with coronary artery disease. © 2006 Elsevier Ireland Ltd. All rights reserved.